CNAM
Campbell Newman Asset Management’s Pacira BioSciences PCRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-35,637
| Closed | -$1.02M | – | 108 |
|
|
2024
Q2 | $1.02M | Buy |
35,637
+59
| +0.2% | +$1.69K | 0.08% | 92 |
|
|
2024
Q1 | $1.04M | Buy |
35,578
+1,515
| +4% | +$44.3K | 0.08% | 88 |
|
|
2023
Q4 | $1.15M | Sell |
34,063
-522
| -2% | -$17.6K | 0.1% | 83 |
|
|
2023
Q3 | $1.06M | Sell |
34,585
-606
| -2% | -$18.6K | 0.1% | 84 |
|
|
2023
Q2 | $1.41M | Buy |
35,191
+781
| +2% | +$31.3K | 0.13% | 70 |
|
|
2023
Q1 | $1.4M | Buy |
34,410
+450
| +1% | +$18.4K | 0.14% | 69 |
|
|
2022
Q4 | $1.31M | Buy |
33,960
+958
| +3% | +$37K | 0.13% | 69 |
|
|
2022
Q3 | $1.76M | Buy |
33,002
+792
| +2% | +$42.1K | 0.2% | 53 |
|
|
2022
Q2 | $1.88M | Buy |
32,210
+1,419
| +5% | +$82.7K | 0.2% | 52 |
|
|
2022
Q1 | $2.35M | Buy |
30,791
+689
| +2% | +$52.6K | 0.23% | 48 |
|
|
2021
Q4 | $1.81M | Buy |
30,102
+14,333
| +91% | +$862K | 0.16% | 65 |
|
|
2021
Q3 | $883K | Buy |
15,769
+777
| +5% | +$43.5K | 0.09% | 90 |
|
|
2021
Q2 | $910K | Buy |
14,992
+832
| +6% | +$50.5K | 0.09% | 90 |
|
|
2021
Q1 | $992K | Buy |
+14,160
| New | +$992K | 0.1% | 86 |
|